Details for Patent: 7,994,220
✉ Email this page to a colleague
Which drugs does patent 7,994,220 protect, and when does it expire?
Patent 7,994,220 protects SAVELLA and is included in one NDA.
This patent has thirty-three patent family members in twenty-three countries.
Summary for Patent: 7,994,220
| Title: | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| Abstract: | The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS. |
| Inventor(s): | Srinivas G. Rao, Michael Gendreau, Jay D. Kranzler |
| Assignee: | Allergan Pharmaceuticals International Ltd |
| Application Number: | US11/535,237 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,994,220 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 7,994,220
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-001 | Jan 14, 2009 | AB | RX | Yes | No | 7,994,220 | ⤷ Start Trial | MANAGEMENT OF FIBROMYALGIA | ⤷ Start Trial | |||
| Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-002 | Jan 14, 2009 | AB | RX | Yes | No | 7,994,220 | ⤷ Start Trial | MANAGEMENT OF FIBROMYALGIA | ⤷ Start Trial | |||
| Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-003 | Jan 14, 2009 | AB | RX | Yes | Yes | 7,994,220 | ⤷ Start Trial | MANAGEMENT OF FIBROMYALGIA | ⤷ Start Trial | |||
| Abbvie | SAVELLA | milnacipran hydrochloride | TABLET;ORAL | 022256-004 | Jan 14, 2009 | AB | RX | Yes | No | 7,994,220 | ⤷ Start Trial | MANAGEMENT OF FIBROMYALGIA | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,994,220
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006294645 | ⤷ Start Trial | |||
| Brazil | PI0617541 | ⤷ Start Trial | |||
| Canada | 2624018 | ⤷ Start Trial | |||
| China | 101355930 | ⤷ Start Trial | |||
| Costa Rica | 9882 | ⤷ Start Trial | |||
| Ecuador | SP088407 | ⤷ Start Trial | |||
| European Patent Office | 1928446 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
